The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself - And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
Five Under-the-Radar Stocks With Catalysts Already in Motion - Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security
The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.